Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Meiji Launches Japan PIII of mRNA COVID Shot for BA.4/5 Strain
Meiji Seika Pharma said on September 29 that it has initiated a PIII booster trial in Japan to investigate ARCT-2301, a bivalent self-amplifying mRNA COVID-19 vaccine based on the ancestral strain and Omicron BA.4/5 subvariants of the novel coronavirus. The…
To read the full story
Related Article
- Meiji Seeks Booster Nod for COVID-19 mRNA Vaccine in Japan
July 3, 2023
- Meiji Files CSL Seqirus’ mRNA COVID Vaccine in Japan
May 1, 2023
- Meiji/CSL Seqirus Tie Up for Sales of COVID-19 mRNA Vaccine in Japan
April 12, 2023
- Mejii Kicks Off Japan PIII for Arcturus’ COVID mRNA Vaccine
December 14, 2022
- Meiji Pharma Eyes Japan Filing of Arcturus’ COVID Vaccine Next Spring
November 2, 2022
- Meiji Pharma in Talks on Japan Rights to Arcturus’ COVID Jab Candidate
August 26, 2022
BUSINESS
- Merck Biopharma Starts Japan PIII Trial of LH/FSH Combo
July 17, 2026
- Eisai’s Dayvigo Accepted for EMA Review
July 17, 2026
- AbbVie Files Maviret for Acute Hepatitis C
July 17, 2026
- Ferring’s Adstiladrin, Boehringer’s Jascayd Hit Market; Haizexin Due July 28
July 16, 2026
- Nipro Pharma Recalls Topical Drugs over Long-Running Manufacturing Deviations
July 16, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…